Back to search
FDAFDA · Food and drugs·Recall number D-0611-2026

Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04.

Published July 1, 2026 · Recall initiated: May 28, 2026

Summary

FDA records drug Class II recall D-0611-2026, published July 1, 2026 and initiated May 28, 2026. Recalling firm: Ajanta Pharma USA Inc; Status: Ongoing; Reported quantity: 3648 bottles; Lot: Lot # PA02216; Exp. 12/2029. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated

Get an email if FENOFIBRATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
FENOFIBRATE
Manufacturer
Ajanta Pharma USA Inc
Distributor
U.S. Nationwide
UPC
0327241119040
Lot
Lot # PA02216; Exp. 12/2029
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Fenofibrate Capsules, USP 200 mg, Rx only, 100 Capsules, Manufactured by: Ajanta Pharma Limited, India, Marketed by: Ajanta Pharma USA Inc. Bridgewater, NJ 08807, NDC 27241-120-04. recalled?

Yes. FDA published recall D-0611-2026 on July 1, 2026. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: FENOFIBRATE. UPC: 0327241119040.